In addition, we show an increased dysregulation of transduction signaling pathways, during different growth phases of SP3 vs. NSP2 development, suggesting targeting specific DEGs during different growth periods may lend to better carcinogenic therapeutic strategies in mammary tumors. The gene discussed is SP3; the disease is breast cancer.